Eriksson Louise, Czene Kamila, Rosenberg Lena U, Törnberg Sven, Humphreys Keith, Hall Per
Breast Cancer Res. 2013 Jun 20;15(3):R48. doi: 10.1186/bcr3440.
Mammographic density (MD) is the strongest risk factor for breast cancer. It is also strongly associated with interval cancers (ICs) due to decreased screening sensitivity and possibly by also giving rise to more aggressive tumors. With this information as background, we compared survival in interval and screen-detected cancers, taking MD into consideration.
The patients were postmenopausal women ages 50 to 74 years who were diagnosed with breast cancer in Sweden between 1993 and 1995. A total of 1,115 women with screen-detected cancers and 285 with ICs had available mammograms. Cox proportional hazards models were used to compare breast cancer-specific survival between interval and screen-detected cancers stratified on MD.
Hazard rates for breast cancer-specific survival were approximately three times higher in ICs than in screen-detected cancers, independent of MD. After adjustment for tumor size, a proxy for time to diagnosis, ICs in nondense breasts still had a statistically significantly increased hazard rate compared to screen-detected cancers in nondense breasts (5-yr survival hazard ratio (HR) 2.43, P = 0.001). In dense breasts, however, there was no longer evidence of a difference in survival between ICs and screen-detected cancers (5-yr survival HR 1.41, P = 0.486).
In nondense breasts, ICs seem to be truly more aggressive than screen-detected cancers. In dense breasts, the poorer prognosis of ICs compared to that of screen-detected cancers may be attributable at least partially to later detection. However, to the best of our knowledge, this study is the first to investigate these relationships, and further studies are warranted to confirm our results.
乳腺钼靶密度(MD)是乳腺癌最强的风险因素。由于筛查敏感性降低,且可能导致更具侵袭性的肿瘤,它还与间期癌(IC)密切相关。基于此背景信息,我们在考虑MD的情况下,比较了间期癌和筛查发现癌的生存率。
研究对象为1993年至1995年间在瑞典被诊断为乳腺癌的50至74岁绝经后女性。共有1115例筛查发现癌的女性和285例间期癌的女性有可用的乳腺钼靶片。采用Cox比例风险模型比较按MD分层的间期癌和筛查发现癌之间的乳腺癌特异性生存率。
无论MD如何,间期癌的乳腺癌特异性生存风险率比筛查发现癌高约三倍。在调整肿瘤大小(诊断时间的一个替代指标)后,非致密乳腺中的间期癌与非致密乳腺中筛查发现癌相比,其风险率仍有统计学显著升高(5年生存风险比(HR)2.43,P = 0.001)。然而,在致密乳腺中,不再有证据表明间期癌和筛查发现癌在生存率上存在差异(5年生存HR 1.41,P = 0.486)。
在非致密乳腺中,间期癌似乎确实比筛查发现癌更具侵袭性。在致密乳腺中,间期癌与筛查发现癌相比预后较差可能至少部分归因于发现较晚。然而,据我们所知,本研究是首次调查这些关系,需要进一步研究来证实我们的结果。